Altair
Skip to content

Trading Analysis Report: ARM

Analysis date: 2026-10-21 · Model: claude-opus-5-5 · AI-generated, not financial advice.

  • Analysis date: 2026-10-21
  • Rating: Underweight
  • Generated: 2026-10-21 13:53:48
  • TradingAgents 0.6.0: anthropic, deep claude-opus-5-5, quick claude-sonnet-5-5
  • Analysts: market, sentiment, news, fundamentals; research debate rounds 5, risk debate rounds 5
  • Data vendors: core_stock_apis yfinance, technical_indicators yfinance, fundamental_data sec_edgar,yfinance, news_data yfinance, macro_data fred, prediction_markets polymarket

V. Portfolio Manager Decision

Rating: Underweight

Price target: 208.45 over 1–2 months, about 8% below the current price.

7. Risks and watch items

  1. Valuation: 234x trailing earnings, about 47x sales and an FCF yield below 1% leave little room for a growth or margin miss.
  2. Margin compression: Operating expenses are growing about 5 points faster than revenue, and Q1 margins have fallen three years in a row. Watch whether the Q2 FY27 operating margin recovers from Q1's 7.1%.
  3. Earnings quality: GAAP net income is running well above operating income, and the Q1 FY27 gap was about $179M. Look for the source (tax, interest or other income) in the filings.
  4. Cash flow volatility: OCF swung from $1,090M to $397M to $1,524M across FY24–FY26, and the $902M June-quarter figure is probably timing-driven.
  5. Rising capital intensity: Capex is up about 6x in two years. Whether it earns a return depends on how it is being used.
  6. Price volatility: The beta of 3.79 and a 52-week range of $100–$453 mean large swings. The stock moved from about $415 to about $227 in under five months.
  7. Upcoming catalyst: The quarter ending Sep 30 has not been reported, since the latest data is June 2026. Based on prior-year timing, results are probably due in early November, but the tools don't confirm the date. The Q4 FY26 versus Q1 FY27 pattern suggests quarterly results can swing sharply.

Limits of this data: - It comes from SEC EDGAR facts via the tools. - It has no segment split (royalty vs. licensing), no remaining performance obligations, no guidance, no R&D/SG&A/SBC detail and no news or analyst data. - Fiscal Q4 columns are absent from the quarterly statements, so I derived them from the annual figures.